Phase 3 N=304 AScalate: Treat-to-target in Axial Spondyloarthritis
Axial Spondyloarthritis
Primary: Percentage of Patients Achieving an ASAS40 Response at Week 24 — 40.1; 49.2 Percentage of participants — p=0.119
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=58 Predicting Ipsilesional Motor Deficits in Stroke With Dynamic Dominance Model
Stroke
Primary: Change in Jebsen-Taylor Hand Function Test (JTHFT) Times From Baseline 2 to Post Test 1 — 5.07; -.11 seconds — p=<.05
Phase 2 N=34 Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
Lung Cancer · Lung Metastases
Primary: Number of Patients Who Are Free From Pulmonary Exacerbations — 72; 40 percental of participants
Phase 2 N=402 Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery in Subjects Undergoing Bowel Resection
Enhanced Recovery After Surgery
Primary: Time to Gastrointestinal Recovery (GIR) — 32.6; 30.8; 33.4 hours — p=0.767
Phase 2 N=25 A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
Colorectal Cancer
Primary: RXC004 Monotherapy (Arm A): Disease Control Rate (DCR) Using Each Patient's Best Overall Response (BOR) According to Response Evaluation Criteria in Solid Tumours…
N/A N=256 Improving Cardiovascular Risk Factors in Black Young Adults
Obesity
Primary: Change in Body Weight — -2.5; -0.8 Pounds
N/A N=443 Balance: A Pragmatic Trial of a Digital Health Intervention to Prevent Weight Gain in Primary Care
Obesity · Overweight · Overnutrition
Primary: Change in Weight at 24-months — 28; 29; 88; 90 Participants — p=0.97
N/A N=55 Virtual Empowered Relief for Chronic Pain
Chronic Pain · Pain
Primary: Perceived Usefulness — 8.25 score on a scale
Phase 4 N=17 A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)
Waldenstrom Macroglobulinemia
Primary: Overall Response Rate (ORR) — 70.6 Percentage of Participants
Phase 3 N=235 A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
Migraine
Primary: Mean Change From Baseline in Monthly Average Number of Migraine Days During 12-Week Period After the First Dose of Study Drug — -1.4; -2.5 days/month — p=0.0210
Phase 4 N=84 Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
SLE · Lupus Nephritis · SGLT2 Inhibitors
Primary: Effect of Dapagliflozin Compared to Placebo on Renal Function After One Year — 128; 114; 115.7; 100.3 mL/min/1.73 m²
N/A N=102 Evaluating Public Health Interventions to Improve COVID-19 Testing Among Underserved Populations
COVID-19
Primary: Recommended Testing Proportion — 0.66 proportion of times tested asrecommended
Phase 1 N=45 MIBG With Dinutuximab +/- Vorinostat
Neuroblastoma
Primary: MTD/RP2D Determination Cohort A — 0; 0; 0 Participants
N/A N=69 Pain Informed Movement for People With Knee Osteoarthritis
Knee Osteoarthritis
Primary: Percentage of Follow up — 28; 31 Participants
Phase 2 N=29 Lenvatinib and Pembrolizumab Simultaneous Combination Study
Advanced Gastric Cancer
Primary: Objective Response Rate (ORR) — 1; 19; 9; 0 Participants